Conference intelligence - CI on the bio-similar companies

Background and objectives

Our client wanted to understand the culture, operations, tactics and strategies of key bio-similar companies (Sandoz, Teva, Stada, Hexal and Ratiopharm) via the 7th EGA Annual Symposium on Biosimilar Medicines.

Approach

Lifescience Dynamic's team undertook secondary intelligence before the conference and sent two consultants with expertise in bio-similars. Our approach also took account of any counter-intelligence activities that might have been taking place at the conference such as mis-information or any 'decoy' activities; our consultants were primed beforehand to recognise them. This enabled us not only to develop key hypotheses but also to test them at the congress. These were rejected or validated once the information was corroborated by a trusted source.

Results delivered

• Provided analysis and commentary on key BS trials
• Analysis of competitor companies' trials and communication strategies
• Summary report on key products:
  • Epoetin (anemia associated with chronic kidney failure)
  • Filgrastim (neutropenia in cancer patients)
  • Insulin
  • Interferon alfa